Renexxion is committed to delivering benefits to patients in need by developing naronapride to approval and to becoming a leading GI biopharmaceutical company.
Renexxion Innovation There is a large unmet medical need for patients suffering from functional Gastro-intestinal disorders. Naronapride, a late-development stage, Phase-3 ready, oral gastro-prokinetic drug in the class of 5-HT4 agonists has shown to be effective fo...
Renexxion is committed to delivering benefits to patients in need by developing naronapride to approval and to becoming a leading GI biopharmaceutical company.
Renexxion Innovation There is a large unmet medical need for patients suffering from functional Gastro-intestinal disorders. Naronapride, a late-development stage, Phase-3 ready, oral gastro-prokinetic drug in the class of 5-HT4 agonists has shown to be effective for a range of these disorders.Renexxion Ireland is committed to delivering benefits to patients in need by developing naronapride to approval and to becoming a leading GI biopharmaceutical company.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.